Summary
Global Markets Direct’s, ‘Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Review, H2 2016’, provides in depth analysis on Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted pipeline therapeutics.
The report provides comprehensive information on the Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12)
- The report reviews Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AstraZeneca Plc
C&C Research Laboratories
CymaBay Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
Wellstat Therapeutics Corp
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Overview 7
Therapeutics Development 8
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Stage of Development 8
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Therapy Area 9
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Indication 10
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Products under Development by Companies 13
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Companies Involved in Therapeutics Development 19
AstraZeneca Plc 19
C&C Research Laboratories 20
CymaBay Therapeutics Inc 21
Jiangsu Hengrui Medicine Co Ltd 22
Nippon Chemiphar Co Ltd 23
Wellstat Therapeutics Corp 24
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Drug Profiles 25
(allopurinol + lesinurad) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
arhalofenate - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
JPH-367 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
NC-2700 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
RLBN-1001 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SHR-4640 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
URC-102 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
verinurad - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
WT-2107 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Dormant Projects 39
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Discontinued Products 40
Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) - Featured News & Press Releases 41
Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology 41
Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate 42
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 43
Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents 44
Jun 12, 2015: CymaBay Therapeutics Presents Poster at EULAR 2015 44
Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City 45
Mar 03, 2015: Vince & Associates Clinical Research Completes CymaBay Therapeutics Clinical Trial of Arhalofenate in Combination with Febuxostat 46
Feb 24, 2015: CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares 46
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 47
Sep 29, 2014: CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout 49
Mar 26, 2014: CymaBay Initiates Arhalofenate Phase 2b Gout Study 49
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 49
Nov 07, 2011: Ardea Biosciences Presents Initial Clinical Results For RDEA3170 At 2011 ACR/ARHP Annual Scientific Meeting 50
Nov 01, 2011: Metabolex To Present Data On Arhalofenate At 2011 ACR/AHP Annual Scientific Meeting 51
May 19, 2011: Metabolex Initiates Phase II Trial Of Arhalofenate For Treatment Of Gout 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by AstraZeneca Plc, H2 2016 19
Pipeline by C&C Research Laboratories, H2 2016 20
Pipeline by CymaBay Therapeutics Inc, H2 2016 21
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 22
Pipeline by Nippon Chemiphar Co Ltd, H2 2016 23
Pipeline by Wellstat Therapeutics Corp, H2 2016 24
Dormant Projects, H2 2016 39
Discontinued Products, H2 2016 40
List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Actions, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
